Epstein-Barr Virus Infections
Information
- Disease name
- Epstein-Barr Virus Infections
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00058591 | Completed | Phase 1 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | January 2000 | December 2008 |
| NCT00058604 | Completed | Phase 1 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | January 2001 | December 2008 |
| NCT00058812 | Completed | Phase 1 | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts | May 1993 | July 2014 |
| NCT00070785 | Completed | Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations | October 6, 2003 | April 21, 2008 | |
| NCT00701922 | Completed | Surveillance Study of Viral Infections Following Lung Transplantation | October 2005 | December 2007 | |
| NCT00963248 | Completed | EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients | July 2003 | August 2010 | |
| NCT01070797 | Completed | Phase 1 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | January 2011 | April 2014 |
| NCT01094405 | Completed | Phase 2 | Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy | March 31, 2010 | August 27, 2020 |
| NCT01256853 | Completed | Phase 1 | Modified Vaccinia Ankara (MVA) Vaccine Study | September 2006 | September 2010 |
| NCT01535885 | Completed | Phase 1 | Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV | February 2012 | October 2019 |
| NCT01972035 | Completed | Phase 2 | ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation | August 1, 2014 | February 28, 2021 |
| NCT02335437 | Completed | Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents | March 2015 | June 2017 | |
| NCT02715752 | Completed | A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin | January 2016 | March 2016 | |
| NCT03374566 | Completed | Immunodeficiency for Severe Epstein-Barr Virus Infection | December 1, 2017 | February 1, 2023 | |
| NCT03546101 | Completed | Early Detection of Epstein-Barr Virus Related Disease. | November 1, 2017 | May 1, 2023 | |
| NCT04693637 | Completed | Phase 2/Phase 3 | Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | January 15, 2021 | January 19, 2023 |
| NCT06002802 | Completed | Study on Infectious Mononucleosis in Munich | March 1, 2016 | August 31, 2020 | |
| NCT06027879 | Enrolling by invitation | Phase 1/Phase 2 | Anti-viral T-cell Therapy by Gamma Capture | January 8, 2024 | June 1, 2029 |
| NCT05592626 | Recruiting | Phase 1/Phase 2 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | January 4, 2023 | October 2026 |
| NCT03266653 | Recruiting | Phase 2 | EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | July 7, 2020 | December 31, 2025 |
| NCT04989491 | Recruiting | Phase 4 | Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft | December 1, 2021 | December 1, 2029 |
| NCT02580539 | Recruiting | Phase 1/Phase 2 | A Study of the Safety and Efficacy of EBV Specific T-cell Lines | November 2015 | August 2024 |
| NCT05183490 | Recruiting | Phase 1 | R-MVST Cells for Treatment of Viral Infections | May 3, 2022 | December 2026 |
| NCT03258567 | Recruiting | Phase 2 | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | April 26, 2018 | June 1, 2031 |
| NCT03769467 | Terminated | Phase 1/Phase 2 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | February 19, 2019 | August 19, 2021 |
| NCT05305040 | Terminated | Phase 2/Phase 3 | Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | March 24, 2022 | January 30, 2024 |
| NCT04507477 | Unknown status | Phase 1/Phase 2 | Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial | July 7, 2020 | February 7, 2023 |
| NCT01248598 | Unknown status | The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis | October 2010 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D020031